FDA Maintains U.S. Enrollment Hold On Newron's Phase 3 ENIGMA-TRS 2 Schizophrenia Study

(RTTNews) - Newron Pharmaceuticals (NP5.DE, NWRN.SW) said the U.S. Food and Drug Administration (FDA) has informed the company that a hold on the enrollment of new patients at U.S. sites participating in the Phase 3 ENIGMA-TRS 2 study of evenamide will remain in place.